|
Guiadance erhöht, Amarin wie geil: Amarin's stock surges after raised revenue outlook, increased commercial expansion of Vascepa Published: July 2, 2019 6:47 a.m. ET Author photo By Tomi Kilgore Reporter and editor Shares of Amarin Corp. AMRN, -0.77% surged 9.2% in premarket trading Tuesday, after the pharmaceutical company raised its full-year revenue outlook and announced plans to double its U.S. sales force to further increase commercial expansion of Vascepa for the treatment of cardiovascular disease. The company now expects 2019 revenue of $380 million to $420 million, above previous guidance of $350 million, and above the FactSet consensus of $364.3 million. Amarin said it increasing the size of its U.S. sales force to about 800 representatives, with the aim of having the expanded team deployed by October. The accelerated expansion followed the priority review designation of the supplemental new drug application (sNDA) for Vascepa. "We anticipate Vascepa revenue growth to accelerate further after label expansion approval and with a larger sales team, and then again after we commence promotion of Vascepa for cardiovascular risk reduction on television and through other media," said Chief Executive John Thero. Amarin's stock has soared 41.4% year to date through Monday, while the S&P 500 SPX, +0.77% has climbed 18.3%. |
|
| aus der Diskussion: | Amarin - The Science Of Lipid Therapy |
| Autor (Datum des Eintrages): | Magnetfeldfredy (02.07.19 12:53:36) |
| Beitrag: | 516 von 1,840 (ID:60935701) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |